Valneva Shares Fall as UK Revokes Ixchiq Vaccine Approval

Key Facts

Valneva shares fell following the United Kingdom's decision to revoke the authorization for its Ixchiq vaccine. Investing.com reported that the decline was triggered by the loss of regulatory backing in the UK market for one of the company's key vaccine products.

The stock experienced downward pressure as British regulatory authorities withdrew accreditation for the treatment. This regulatory setback occurred in a broader economic context where the UK inflation rate was recorded at 3.3% on September 2, 2026, according to recent economic data.